Paper33764385
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
Del Paggio JC and 6 others. JAMA Oncol, 2021. Cited by 185 papers, by iCite.
Cite this record
ConductScience Library. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. Papers, record 33764385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33764385
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Drug Industry | |
| Humans | |
| Medical Oncology | |
| Progression-Free Survival |
Source PubMed
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 34436516 | Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity-Reply. | https://conductscience.org/library/papers/34436516 | PubMed |
| Comment in | 34436547 | Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity. | https://conductscience.org/library/papers/34436547 | PubMed |
| Comment in | 34436567 | Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity. | https://conductscience.org/library/papers/34436567 | PubMed |
| Comment in | 34436578 | Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity. | https://conductscience.org/library/papers/34436578 | PubMed |
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26101248 | American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26101248 | PubMed |
| 2 | 24803662 | High cancer drug prices in the United States: reasons and proposed solutions. | J Oncol Pract | 2014 | https://conductscience.org/library/papers/24803662 | PubMed |
| 3 | 32885898 | Professional Medical Writer Assistance in Oncology Clinical Trials. | Oncologist | 2020 | https://conductscience.org/library/papers/32885898 | PubMed |
| 4 | 22048151 | Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. | Ann Oncol | 2012 | https://conductscience.org/library/papers/22048151 | PubMed |
| 5 | 22370321 | Progression-free survival: meaningful or simply measurable? | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22370321 | PubMed |
| 6 | 28453694 | Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28453694 | PubMed |
| 7 | 28978555 | Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. | BMJ | 2017 | https://conductscience.org/library/papers/28978555 | PubMed |
| 8 | 27281466 | An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials. | JAMA Oncol | 2016 | https://conductscience.org/library/papers/27281466 | PubMed |
| 9 | 28027518 | Impact of industry collaboration on randomised controlled trials in oncology. | Eur J Cancer | 2017 | https://conductscience.org/library/papers/28027518 | PubMed |
| 10 | 30374970 | Association between progression-free survival and patients' quality of life in cancer clinical trials. | Int J Cancer | 2019 | https://conductscience.org/library/papers/30374970 | PubMed |
| 11 | 33507236 | An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33507236 | PubMed |
| 12 | 30285081 | Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis. | JAMA Intern Med | 2018 | https://conductscience.org/library/papers/30285081 | PubMed |
| 13 | 20525992 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20525992 | PubMed |
| 14 | 19951955 | Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. | Ann Oncol | 2010 | https://conductscience.org/library/papers/19951955 | PubMed |
| 15 | 10968436 | The uncertainty principle and industry-sponsored research. | Lancet | 2000 | https://conductscience.org/library/papers/10968436 | PubMed |
| 16 | 32815984 | Association of Industry Sponsorship With Cancer Clinical Trial Accrual. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32815984 | PubMed |
| 17 | 33412270 | Have investigators forgotten how to write? | Ann Oncol | 2021 | https://conductscience.org/library/papers/33412270 | PubMed |
| 18 | 30572165 | New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. | Cancer Treat Rev | 2019 | https://conductscience.org/library/papers/30572165 | PubMed |
| 19 | 28583794 | Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28583794 | PubMed |
| 20 | 26098871 | The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. | JAMA Intern Med | 2015 | https://conductscience.org/library/papers/26098871 | PubMed |
Cited by103
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42985096 | Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries. | Front Oncol | 2026 | https://conductscience.org/library/papers/42985096 | PubMed |
| 42789933 | Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA). | Oncologist | 2026 | https://conductscience.org/library/papers/42789933 | PubMed |
| 42740735 | Clinical practice guideline recommendations can promote or undermine health equity. | Clin Public Health Guidel | 2025 | https://conductscience.org/library/papers/42740735 | PubMed |
| 42583054 | An overview of clinical trials in anal cancer 1999-2024. | ESMO Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42583054 | PubMed |
| 42518588 | Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports. | Front Public Health | 2026 | https://conductscience.org/library/papers/42518588 | PubMed |
| 42518232 | Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review. | JAMA Netw Open | 2026 | https://conductscience.org/library/papers/42518232 | PubMed |
| 42465577 | Comparative study of three treatment approaches on overall survival and treatment response in nasopharyngeal carcinoma patients: network meta-analysis of RCTs (4221 patients). | Front Oncol | 2026 | https://conductscience.org/library/papers/42465577 | PubMed |
| 42448890 | Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II. | Eur J Nucl Med Mol Imaging | 2026 | https://conductscience.org/library/papers/42448890 | PubMed |
| 42443603 | Evolution of randomized controlled trials in adult neurosurgical critical care from 1990 to 2024 in the United States. | Neurosurg Rev | 2026 | https://conductscience.org/library/papers/42443603 | PubMed |
| 42406651 | Progression-Free Survival Effect Sizes in Randomized Controlled Trials of Targeted Cancer Therapies with Positive Outcomes. | Acta Haematol | 2026 | https://conductscience.org/library/papers/42406651 | PubMed |
| 42270817 | Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/42270817 | PubMed |
| 41915264 | The use of endpoints in phase 3 randomized controlled trials in metastatic breast cancer. | Breast Cancer Res Treat | 2026 | https://conductscience.org/library/papers/41915264 | PubMed |
| 41889619 | From methods to policy: a critical appraisal of the 2024 ECDC guidance on enhanced influenza vaccines. | Front Public Health | 2026 | https://conductscience.org/library/papers/41889619 | PubMed |
| 41777410 | Oncology with common sense: beyond biologistic and pharmacological models. | Ecancermedicalscience | 2026 | https://conductscience.org/library/papers/41777410 | PubMed |
| 41699553 | Accelerating cancer therapy review: a cross-sectional analysis of expedited approval in China, 2005-2021. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41699553 | PubMed |
| 41694651 | Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis. | Liver Cancer | 2026 | https://conductscience.org/library/papers/41694651 | PubMed |
| 41688575 | Comparison of primary analysis strategies of randomized controlled trials with multiple endpoints with application to kidney transplantation. | Sci Rep | 2026 | https://conductscience.org/library/papers/41688575 | PubMed |
| 41647347 | Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review. | ESMO Real World Data Digit Oncol | 2025 | https://conductscience.org/library/papers/41647347 | PubMed |
| 41512959 | Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum. | J Cancer Policy | 2026 | https://conductscience.org/library/papers/41512959 | PubMed |
| 41491679 | Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41491679 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33764385
GET https://conductscience.org/api/papers/v1/33764385/references?page=2